Alice Shaw, MD, Ph.D, GRACE Faculty

Alice T. Shaw is the Director of the Center for Thoracic Cancers and the Paula O’Keeffe Endowed Chair of Thoracic Oncology at Massachusetts General Hospital. She is also an Associate Professor of Medicine at Harvard Medical School. She received her A.B. in Biochemistry from Harvard and her M.D. and Ph.D. degrees from Harvard Medical School. She did her residency in Internal Medicine at Massachusetts General Hospital and completed a fellowship in Hematology/Oncology at Dana-Farber/Massachusetts General Hospital. She completed her postdoctoral work in the laboratory of Dr.

Karen Reckamp, MD, MS, GRACE Faculty

Karen Reckamp, MD, MS, is Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center (COHCCC). She received her medical degree from University of Chicago, and her master’s degree in Clinical Investigation from UCLA. She completed residency training in Internal Medicine at Barnes-Jewish Hospital and a Hematology/Oncology fellowship at the David Geffen School of Medicine at UCLA.

Janet Freeman-Daily, Patient Advocate, Live Forum Moderator

Janet Freeman-Daily is a writer, science geek, and lung cancer patient/activist. She received a diagnosis of advanced non-small cell lung cancer in May 2011 which became metastatic despite chemotherapy and radiation. After learning about genomic testing and precision medicine in online patient communities, she joined a clinical trial for ROS1-positive lung cancer and has had no evidence of disease for over four years.

 

Heather Wakelee, MD, GRACE Faculty

Dr. Wakelee is an assistant professor of medicine at Stanford University in the Division of Oncology where she is the co-leader of the lung cancer disease management group. Her focus is in clinical research in lung cancer patients, and she has a particular interest in anti-angiogenesis agents. Dr. Wakelee is the principal investigator of the ongoing International Lung Cancer Intergroup Trial E1505 that is investigating the potential role of bevacizumab in addition to adjuvant chemotherapy for resected early-stage, non-small cell lung cancer.

Rachel Sanborn, MD, GRACE Faculty

After graduating from Oregon Health & Science University with her medical degree, Dr. Rachel Sanborn completed her residency in internal medicine at the University of Illinois at Chicago. Then she returned to Portland for her Fellowship in Hematology and Medical Oncology at Oregon Health & Science University. She is board-certified in medical oncology and internal medicine.

Pages

Subscribe to CancerGRACE RSS